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Aim: To use Monte Carlo (MC) together with voxel phantoms to analyze the tissue hetero-
geneity effect in the dose distributions and equivalent uniform dose (EUD) for 125I prostate
implants.
Background: Dose distribution calculations in low dose-rate brachytherapy are based on
the  dose deposition around a single source in a water phantom. This formalism does not
take into account tissue heterogeneities, interseed attenuation, or ﬁnite patient dimensions
effects. Tissue composition is especially important due to the photoelectric effect.
Materials and methods: The computed tomographies (CT) of two patients with prostate cancer
were used to create voxel phantoms for the MC simulations. An elemental composition andMonte Carlo
Tissue heterogeneity
density were assigned to each structure. Densities of the prostate, vesicles, rectum and
bladder were determined through the CT electronic densities of 100 patients. The sameModel-based calculation algorithms simulations were performed considering the same phantom as pure water. Results were
compared via dose–volume histograms and EUD for the prostate and rectum.
Results: The mean absorbed doses presented deviations of 3.3–4.0% for the prostate and of
2.3–4.9% for the rectum, when comparing calculations in water with calculations in the
Abbreviations: LDRBT, low dose-rate brachytherapy; AAPM TG, American Association of Physicists in Medicine Task Group; PS, planning
system; MC, Monte Carlo; CT, computerized tomography; MBDCA, model-based dose calculation algorithm; DVH, dose–volume histogram;
dDVH,  differential dose–volume histogram; EUD, equivalent uniform dose; TCP, tumor control probability (TCP); NTCP, normal tissue
complication probability; EBRT, external beam radiotherapy; OAR, organ at risk; HT, heterogeneous; W,  water.
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heterogeneous phantom. In the calculations in water, the prostate D90 was overestimated
by  2.8–3.9% and the rectum D0.1cc resulted in dose differences of 6–8%. The EUD resulted in
an  overestimation of 3.5–3.7% for the prostate and of 7.7–8.3% for the rectum.
Conclusions: The deposited dose was consistently overestimated for the simulation in water.
In  order to increase the accuracy in the determination of dose distributions, especially
around the rectum, the introduction of the model-based algorithms is recommended.
©  2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
1
L
p
m
o
a
b
s
s
i
t
a
p
d
t
m
t
t
a
u
p
f
s
6
f
r
p
c
o
2
t
f
p
f
c
n
i
v
d
b
c
v
d
t
with prostate cancer. These patients had a median age of
68 years old, median of prostate volume of 58.2 cm3, and a
median Gleason score of 7. In order to evaluate the tissue het-
erogeneity inﬂuence in the dose distributions, a comparison.  Background
ow dose-rate brachytherapy (LDRBT), using 125I and 103Pd
ermanent implants, has become very popular in the treat-
ent of early stage prostate cancer. The American Association
f Physicists in Medicine (AAPM) Task Group No. 43 (TG-43)1
nd the updated report (TG-43U1)2 recommended a water-
ased dose calculation formalism for this low-energy emitting
ources. The dose deposition is described around a single
ource in a spherical water phantom and then interpolated
n order to obtain tables of absorbed dose to be used in
he planning systems (PS). However, the inﬂuence of tissue
nd applicator heterogeneities, interseed attenuation, or ﬁnite
atient dimensions can signiﬁcantly change the absorbed
ose values in the PS.3 Moreover, for low-energy sources,
he photoelectric effect predominates and differences in the
ass-energy absorption coefﬁcients between water and other
issues may result in signiﬁcant differences in dose distribu-
ions.
Chibani et al.4 investigated the effects of seed anisotropy
nd interseed attenuation for 103Pd and 125I prostate implants
sing Monte Carlo (MC) methods for two idealized and two real
rostate implants. Absolute total dose differences between
ull MC  simulations and point-source dose-kernel superpo-
ition were as high as 7.4% for the idealized model and
.1% for the clinical model for the 103Pd implants and 4.4%
or the idealized and 4.6% for the clinical for the 125I. Car-
ier et al.5 found deviations of 6.8% for the prostate D90
arameter (dose achieving 90% of the target volume) when
omparing a clinical technique to a full MC simulation,
f which 4.3% were due to the interseed attenuation and
.5% to the tissue composition. Hanada et al.6 compared
he TG-43U1 parameters,  and gL(r), using MC simulations,
or water and prostate tissue. The comparison of the D90
rostate parameter showed a dose underestimation of 1.7%
or the prostate tissue relative to water. CT-based studies
omparing homogeneous water phantom with a heteroge-
eous phantom revealed a dose underestimation of 2.8 Gy
n D907 and a decrease of 5.6% in the tissue irradiated
olume.8
In order to overcome these issues, new model-based
ose calculation algorithms (MBDCA) are now available for
rachytherapy. These algorithms account for heterogeneity
orrections. The recently released AAPM report TG-1863 pro-
ides guidance for the use of these algorithms in terms of the
ose-speciﬁcation medium, voxel-by-voxel interaction correc-
ion cross sections, and a commissioning process.2.  Aim
The purpose of this work was to understand the importance of
these MDCAs in terms of the tissue heterogeneity correction.
Dose distributions of LDRBT treatments of prostate cancer
with 125I permanent implants using Monte Carlo methods
were performed in a water medium and in a heteroge-
neous medium with the density and tissue composition of
the prostate and surrounding tissues, and the values com-
pared. For the simulations, we used two anthropomorphic
voxel phantoms extracted from the computed tomography
(CT) of two patients with prostate cancer. Dose deposition
was evaluated on a voxel-by-voxel basis for the prostate
and the rectum and compared via dose–volume histograms
(DVH), equivalent uniform dose (EUD), tumor control prob-
ability (TCP) and normal tissues complication probability
(NTCP).
3.  Materials  and  methods
3.1.  Monte  Carlo  dose  calculations
The simulations were performed using the MCNPX code ver-
sion 27a9 and the default photon scattering cross section
tables from the National Nuclear Data Center’s ENDF/B-VI.8
library10 based on EPDL97.11 CT DICOM images of two  patients
with prostate cancer were segmented using the ImageJ version
1.44p12 software and converted into the MCNPX  code in order
to create two voxel phantoms. A CT of a patient with a small
prostate (prostate A: 31 cm3) and a big prostate (prostate B:
109 cm3) were chosen. The size of each voxel is the same as
the CT voxel: 0.94 mm × 0.94 mm × 5 mm.  To each structure of
interest, a given density and elemental composition (Table 1)
were assigned. The elemental composition of the skin, blad-
der, rectum, prostate, spinal cord, bones and muscle, as well
as skin density, were taken from the ICRP publication 89.13
Elemental compositions of the spinal cord and residual tis-
sue, as well as the respective densities, and muscle and bone
densities were taken from the ICRU 44 report.14 Finally, the
densities of the prostate, vesicles, rectum and bladder were
determined through the CT electronic densities of 100 patients
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Table 1 – Elemental composition and density assigned to each segmented structure in the voxel phantoms.
Medium/tissue Elemental composition (% by mass) Density (g/cm3)
H C N O Na Mg P S Cl K Ca
Water2 11.2 88.8 0.9982
Skin13 10.0 20.4 4.2 64.5 0.2 0.1 0.2 0.3 0.1 1.10013
Bladder13 10.5 9.6 2.6 76.1 0.2 0.2 0.2 0.3 0.3 1.014a
Rectum13,b 10.6 11.5 2.2 75.1 0.1 0.1 0.1  0.2 0.1 0.932a
Prostate13 10.5 25.6 2.7 60.2  0.1 0.2 0.3 0.2 0.2 1.027a
Vesicles13,c 10.5 25.6 2.7 60.2 0.1 0.2 0.3 0.2 0.2 0.989a
Spinal cord14,d 10.7 14.5 2.2 71.2 0.2 0.4 0.2 0.3 0.3 1.04014
Bone13,e 3.5 16.0 4.2 44.5 0.3 0.2 9.5 0.3 21.5 1.92014
Muscle13 10.2 14.3 3.4 71.0 0.1 0.2 0.3 0.1 0.4 1.05014
Residual tissue14,f 11.4 59.8 0.7 27.8 0.1 0.1 0.1 0.95014
a This study.
b Considered alimentary tract stomach and intestine elemental composition.
c Considered prostate tissue elemental composition.
d Considered brain elemental composition and density.
e Adult mineral bone.
f Adipose tissue.
was performed by considering all the mentioned structures as
pure water in the simulations.
The geometry description in the MC  simulations of seeds
were based on the Amersham model 6711seed manufactured
by General Electric Health Care, taken from Dolan et al.15 Seeds
were placed in a modiﬁed peripheral loading, ﬁrst they were
positioned in the periphery of the prostate and then some
seeds were added in the central portion to compensate the low
absorbed doses in the center. A dose prescription of 145 Gy was
considered, with an initial source activity of 0.7 mCi. A total
of 93 seeds were used for prostate A and of 204 for prostate
B. The MCNPX F6 tally, a track-length estimator, was used to
determinate the energy deposition in each voxel in units of
MeV  g−1 photon−1 after the simulation of 1E8 particles.
3.2.  EUD  evaluation
Dose distributions were evaluated by isodose visualization,
DVH and the AAPM TG-13716 dose reporting parameters for
the prostate (V100, V150 and D90) and rectum (V100 and D0.1cc).
Comparison between heterogeneous and water calculations
was also performed via the EUD.
The EUD concept was ﬁrst developed by Niemierko17 for
External Beam Radiotherapy (EBRT). It provides a method for
evaluating non-uniform dose distributions based on models of
clonogen survival. The EUD was later generalized for the eval-
uation of normal tissues.18,19 It is deﬁned as a radiobiological
effective dose that, if delivered uniformly, would result in the
same biological effect as a non-uniform dose distribution or,
for normal tissues, would lead to the same NTCP. Here, the
NTCP is calculated based on the Lyman’s model20 along with
the method of effective volume by Kutcher and Burman.21
Using the differential dose–volume histogram (dDVH) of a
given dose distribution, the generalized EUD to compute the
rectum EUD is given by:gEUD =
(
N∑
i=1
viD
a
i
)1/a
(1)where N is the number of elements in the dDVH, vi is
the fractional organ volume receiving a dose Di and a is a
tissue-speciﬁc parameter that describes the volume effect.
The parameter a is negative for tumors and approaches a
minimum for a → −∞,  and is positive for normal tissues,
approaching a maximum dose for a → +∞ (serial organs).
For brachytherapy treatments, dose distributions are
highly non-uniform and the mean dose does not reﬂect the
biological effectiveness. As such, changes in dose distributions
occurring above or below the mean dose lead to changes in the
treatment outcome. Moreover, the brachytherapy treatment is
highly inﬂuenced by the dose-rate, repair of sublethal damage
and clonogen proliferation effects. Wang and Li22 described
the EUD as a numerical value for any delivery scheme with
respect to that for EBRT delivered in 2 Gy fractions, allowing
for the comparison of different radiotherapy modalities, as
EBRT and LDRBT. For tumors, EUD that results in the surviving
fraction S is calculated by:
EUD = − ln (S)
 ˛ +  ˇ · d − 1.4 · (/d) (2)
where  ˛ and  ˇ characterize intrinsic radiosensitivity,  is the
effective tumor cell repopulation rate ( = ln(2)/Tpot); Tpot is the
tumor-cell potential doubling time, and d is the dose per frac-
tion (d = 2 Gy).
The LQ formalism and survival for LDRBT treatments have
been abundantly discussed.23–25 The surviving fraction for
LDRBT is calculated as follows:
S = e−(˛·D−ˇ·G·D2−·Teff ) (3)where D is the total dose delivered, G is a protraction factor
to account for the repair of sublethal damage, and Teff is the
effective treatment time at which the cell killing rate is too low
to compete with cell repopulation.
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Table 2 – Radiobiological parameters values used for the
EUD, TCP and NTCP calculation for prostate and rectum.
Parameter Value
 (125I) 0.00048 h−1
Prostate
a19 −10
˛27 0.15 Gy−1
Tpot 28,29 42 days, 1008 h
27 2.6 h−1
˛/ˇ30 2.7 Gy
K27 3.0 × 106 cells (intermediate-risk patient group)
k26 0.8154
Rectum
˛/ˇ31 5.5 Gy
32 0.6 h−1
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Fig. 1 – DVH obtained for the prostate A with the Monte
Carlo simulation of 1E8 particles. Straight line: calculations
in the heterogeneous phantom (HT); dashed line:
with the simulations, are shown in Tables 3 and 4.
Regarding the prostate results, the D90 parameter overesti-
mation was of 3.91% for prostate A and of 2.79% for prostatea33 4.3
m33 0.19
TD50 33 81.9 Gy
In order to account for dose distributions heterogeneity, the
verall surviving fraction, S, was calculated through the dDVH
or each dose distribution17,22:
 =
N∑
i=1
vi · S(Di) (4)
here S is the weighted average of the survival fractions taken
ver all N near-homogeneously irradiated sub-volumes of the
arget, and vi is the fractional dose bin Di in the dDVH.To com-
ute the tumor control probability (TCP) from S, the Poisson
tatistics is used:
CP = e−K·S (5)
here K is the tumor clonogen cell number.
For normal tissues, Luxton et al.26 derived an analytical
pproximation to the phenomenological LKB model20,21 in
rder to calculate the EUD for a given NTCP. The expression
o determinate rectum NTCP is as follows:
TCP = 1
2
ek·u−(k
2·u2/2) (6)
he parameter k was derived by Luxton et al.26 in order to ﬁt the
yman equation, and u is a variable from the Lyman model,20
iven by:
 = D − TD50
m · TD50
, (7)
here m is a dimensionless ‘scaling’ parameter, and TD50 is
he whole organ dose for which NTCP is 50%.
The parameter values used to compute the EUD, TCP and
TCP in this work are shown in Table 2.
.  Results.1.  Dose–volume  histograms  (DVH)  results
he DVHs obtained when comparing the results in the hetero-
eneous phantom (HT) and in water (W)  in the two consideredcalculations in water (W).
prostates are shown in Figs. 1–4. For prostate A, the results are
shown in Fig. 1 for the prostate target volume and Fig. 2 for the
rectum A as an organ at risk (OAR). For prostate B, Fig. 3 shows
the prostate DVHs and Fig. 4, the rectum B. Maximum statis-
tical errors were under 1% for prostates A and B, and around
7% for rectum A and 5% for rectum B. Statistical errors for
the rectum are higher due to the lower doses (less particles)
traversing this structure.
The results show that in the calculations where tissue het-
erogeneities are not taken into account, the absorbed dose is
overestimated. A mean absorbed dose overestimation of 3.96%
was obtained for prostate A and of 3.30% for prostate B. For
the rectum, the same differences in the mean absorbed dose
were of 4.86% for rectum A and of 2.28% for rectum B. Clin-
ical endpoints regarding the AAPM TG-13716 dose reporting
parameters, both for the prostate and the rectum, obtainedFig. 2 – DVH obtained for the rectum A with the Monte
Carlo simulation of 1E8 particles. Straight line: calculations
in the heterogeneous phantom (HT); dashed line:
calculations in water (W).
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Table 3 – AAPM TG-13716 dose reporting parameters obtained for the prostates A and B with the simulations in the
heterogeneous phantom (HT) and in water (W).
Dose parameter endpoint Prostate A Prostate B
W HT W HT
V100 > 95% 97% 97% 97% 97%
V150 ≤ 50% 46% 37% 44% 36%
D90 > 90 Gy 186 Gy 179 Gy 184 Gy 179 Gy
Table 4 – AAPM TG-13716 dose reporting parameters obtained for the rectums A and B with the simulations in the
heterogeneous phantom (HT) and in water (W).
Dose parameter endpoint Rectum A Rectum B
W HT W HTV100 < 2 cc 0.06 cc 
D0.1 < 150% 101% 
B, when comparing the heterogeneous (HT) and water (W)
results. Concerning the rectum D0.1 parameter, a dose dif-
ference of 8% was found in rectum A and of 6% in rectum
B.
4.2.  Equivalent  uniform  dose  (EUD)  results
The overestimation of the clinical dose parameters in the cal-
culations in water relative to the heterogeneous medium is
reﬂected in the EUD determined through the DVHs shown in
Figs. 1–4 and Eq. (1) for the rectum and Eqs. (2)–(4) for the
prostate. Results for the EUD, TCP and NTCP are shown in
Tables 5 and 6 for the prostate and rectum, respectively.
Comparing the results obtained in water and in the het-
erogeneous phantom, an equivalent dose overestimation of
3.53% was obtained for prostate A and of 3.70% for prostate
B. These EUD values are reﬂected in a difference of 1% in the
TCP. For rectal lower doses, differences are more  signiﬁcant,
with the equivalent dose overestimated by 7.69% in rectum A
and by 8.33% in rectum B. NTCP are very low for the rectum
structure and a difference of 0.02% was obtained for rectum A
and of 0.01% for rectum B.
Fig. 3 – DVH obtained for the prostate B with the Monte
Carlo simulation of 1E8 particles. Straight line: calculations
in the heterogeneous phantom (HT); dashed line:
calculations in water (W).0.00 cc 0.00 cc 0.00 cc
93% 92% 86%
5.  Discussion
For LDRBT, the photoelectric effect plays a signiﬁcant role, as
the dose distributions are highly dependent on the atomic
number of the irradiated tissue. Regarding, as an example,
the prostate D90 parameter, a dose overestimation between
2.8 and 3.9% was found, when comparing with the results in
water.
Landry et al.34 obtained an overestimation of 2.0% in D90
when comparing the dose transported in a prostate tissue with
elemental composition equivalent to ours but scored in water
with simulations in water. Chibani et al.4 found a dose over-
estimation of 2.5% for the effects of anisotropy and interseed
attenuation for the same D90 parameter comparing a full MC
simulation with a line-source kernel superposition method for
the 125I sources. Considering these two effects, a water-based
calculation with the dose deposition described around a sin-
gle source can lead to a dose overestimation above 6% for D90.
On the other hand, Carrier et al.5 when taking into account
both tissue heterogeneity and interseed attenuation found a
dose overestimation of 7.0% for D90, when comparing a clinical
technique with a MC simulation.
Fig. 4 – DVH obtained for the rectum B with the Monte Carlo
simulation of 1E8 particles. Straight line: calculations in the
heterogeneous phantom (HT); dashed line: calculations in
water (W).
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Table 5 – EUD and TCP obtained for prostates A and B with the simulations in the heterogeneous phantom (HT) and in
water (W).
Prostate A Prostate B
W HT W HT
EUD (Gy) 88 85 84 81
TCP (%) 100.0 99.9 99.9 99.8
Table 6 – EUD and NTCP obtained for rectums A and B with the simulations in the heterogeneous phantom (HT) and in
water (W).
Rectum A Rectum B
W HT W HT
26 
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In addition to the tissue heterogeneity and interseed atten-
ation effects, there are other sources of uncertainty related
o a water dose deposition formalism. For example, prostatic
alciﬁcations are present to some degree in many cases and
end to increase with advancing age.35 The calcium content,
ue to its high cross section, increases the absorption of the
25I X-rays. Meigooni et al.36 had shown that changing the cal-
ium content from 1.7% to 2.3% in a solid water phantom will
hange the conversion factors of a water equivalent material
o water for 125I sources up to 5%.
This study showed that taking into account the tissue het-
rogeneity instead of considering the whole body as pure
ater may change the dose deposition recorded in the LDRBT
reatments with 125I sources. All together, the combination
f the tissue composition with other factors as the interseed
ttenuation and presence of calciﬁcation in the prostate may
onsiderably change the clinical dosimetry parameters. It is
roven, for example, that the D90 correlates with the clini-
al outcome, and it is specially sensitive if it is near 140 Gy.37
he implementation of the MBDCA in the clinical dosimetry of
he LDRBT will allow to overcome most of these uncertainties,
nabling greater accuracy in its dose recording. However, the
ecommendation of the AAPM report TG-186,3 should be care-
ully followed and changes in dose prescription would require
ore clinical trials.
.  Conclusions
C  simulations were performed in voxelized pelvic phantoms
ased on the TC pelvic DICOM images of two patients with
rostate cancer. A speciﬁc elemental composition and den-
ity were assigned to each different structure in order to create
nthropomorphic phantoms. Simulations in these phantoms
ere compared to simulations considering a simple water
hantom with the same body contour to estimate differences
n dose distributions due to the tissue heterogeneity effect.
onsidering either a physical DVH analysis or a biological
UD evaluation, simulations in water overestimate the actual
bsorbed dose distributions. Mean adsorbed dose overestima-
ions between 3.3 and 4.0% were found for the prostate and
etween 2.3 and 4.9% for the rectum. Regarding the EUD evalu-
tion, an overestimation between 3.5 and 3.7% for the prostate
nd between 7.7 and 8.3% for the rectum was obtained. It is
xpected that the new MBDCAs that are being introduced in26 24
 0.04 0.03
the LDRBT PS could reduce these deviations allowing for more
precise dose distribution evaluations in patients with prostate
cancer.
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